Cyteir Therapeutics



Through a unique cancer treatment approach, Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

Barbara Wan
VP, Research & Development Project Leadership
Jean-Marc Lapierre
VP, Chemistry
Susan Doleman
VP, Clinical Operations
Tom O'shea
SVP, Clinical Pharmacology & Preclinical Development
Andrew Gengos
Chief Business Officer
Paul Secrist
Chief Scientific Officer
Judson Englert
VP, Clinical Research & Development
David Gaiero
VP, Finance
Lisa Hayes
VP, Investor Relations & Corporate Communications
Gale Cohen
VP, Human Resources

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.